At a Glance
  • Status: Completed Consortium
  • Year Launched: 2009
  • Initiating Organization: European Comission Seventh Framework Programme (FP7)
  • Initiator Type: Government
  • No disease focus
  • Location: International


High-specificity affinity reagents are essential probes for proteome research because they allow the detection and localization of multiple proteins in tissues and fluids in health and disease. The technologies used for these approaches are collectively known as "Affinity Proteomics." AffinityProteome, a European Union (EU) FP7 collaborative research project among five academic partners and five commercial enterprises (four SMEs), developed tools and technologies for high-throughput research based on affinity reagents to study the human proteome. The project focused on resolving bottlenecks in the high throughput production of quality controlled, recombinant binding molecules of different types (antibody fragments, engineered DARPin scaffolds, nucleic acid aptamers) with advanced applications (capture microarrays, single molecule detection, intracellular knockdown). The targets for binder production and analysis are the proteins of the TGF-ß and MAP kinase signal transduction pathways.


The aim of AffinityProteome is to facilitate and accelerate developments in affinity proteomics for the biotechnology sector by linking producers of recombinant binding molecules with the developers of novel advanced technologies for their application. The binding molecules themselves will encompass both established single-chain antibody fragments and alternative binders of particular promise (ankyrin repeat proteins, nucleic acid aptamers). The innovative technologies of protein microarrays, proximity ligation, and intrabodies will address different areas of binder application.

The project will focus on development of reagents for protein kinases and their targets in cell signaling pathways, which are central to all cellular responses and which, when disregulated, can lead to disorders of cell growth, notably cancers, as well as autoimmunity and a range of other diseases. The specific targets are in the TGF-ß and MAP kinase pathways. The development of validated reagents for detection and potentially modulation of these pathways will be of immediate benefit to clinical research in this vital area and provide new leads for the pharmaceutical industry.

Consortium History

The AffinityProteome proposal was submitted in September 2007 to the Health call 2007-1.1-4 (SME-driven collaborative research projects for developing tools and technologies for high-throughput research) and was approved for negotiation in March 2008. Negotiations were completed and the contract issued in January 2009 and the project started on March 1, 2009, running for three years. The Affinity Proteome project ended in February 2012.

Structure & Governance

 AffinityProteome workplan

Points of Contact

Oda Stoevesandt
Babraham Bioscience Technologies Ltd

Sponsors & Partners

Babraham Bioscience Technologies Ltd

Biaffin GmbH & Co KG

Source BioScience PLC / Geneservice

Olink Bioscience AB

German Cancer Research Centre

Technical University Braunschweig

University Kassel

University Uppsala

SomaLogic, Inc.

University of Zurich

Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.